stockmarketproxy
/
BIIBNasdaq SEC EDGAR

BIOGEN INC.

Biological Products, (No Diagnostic Substances)·CAMBRIDGE, MA·FY end 12/31·CIK 875045
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$9.9B$9.7B$9.8B$10.2B$11.0B
Gross Profit——————
Operating Income————$2.8B—
Net Income$1.3B$1.6B$1.2B$3.0B$1.6B
Operating CF$2.2B$2.9B$1.5B$1.4B$3.6B
Capex$153.8M$153.7M$277.0M$240.3M$258.1M
Free Cash Flow$2.1B$2.7B$1.3B$1.1B$3.4B
Buybacks—$0$0$750.0M$1.8B
Dividends——————
Gross Margin——————
Operating Margin————25.9%—
Net Margin13.1%16.9%11.8%29.9%14.2%
FCF Margin20.7%28.1%12.9%11.2%30.8%
R&D / Revenue——————
Effective Tax16.9%—————
Debt / Equity——0.470.470.58
Buybacks / FCF—0.0%0.0%65.6%53.2%

Peer comparison

Biological Products, (No Diagnostic Substances) · 5 peers
CEO Pay Ratio
BIIB
113:1
EXEL
81:1
GILD
119:1
PCVX
48:1
IBRX
69:1
CGON
6:1
CEO total comp
BIIB
$24M
EXEL
$33M
GILD
$28M
PCVX
$14M
IBRX
$13M
CGON
$12M
Net Margin
BIIB
13.1%
EXEL
33.7%
GILD
28.9%
PCVX
—
IBRX
-310.2%
CGON
—